FOUNTAIN HILLS, Ariz.,
Aug. 24 /PRNewswire-FirstCall/ --
Sunridge International (OTC Bulletin Board: SNDZ), announced today
that it will travel to Europe next
month to have meetings with key brokers and funds. The
purpose of these meetings will be to bring awareness to our
company's technology, and to facilitate funding for Sunridge to
execute its business plan for expansion.
"Now is a good time for this project," states G. Richard Smith, CEO of Sunridge. "We
have had a presence in Europe
through distributors for some time now, and with our recent
expansion into India and the
Middle East, it makes good
sense."
The meeting schedule is being setup by IBIS Consulting LLC, a
consulting firm with 10-years of experience pairing companies with
European investment funds.
Glaucoma is the second leading cause of blindness, affecting
over 70 million people worldwide. PNT has been proven (through
studies completed over the last 10 yrs) to be a safe, effective,
non-invasive and a cost effective alternative for treatment for
glaucoma and ocular hypertension. The 2-minute treatment has been
developed, patented, and distributed by Sunridge International,
wholly owned subsidiary, Ophthalmic International
(www.oi-pnt.com).
|
CONTACT:
|
|
|
Jeff Smith,
Sunridge International
|
|
|
T:
+1-480-837-6165
|
|
|
e-mail:
info@sunridgeint.com
|
|
|
|
|
MEDIA:
|
|
|
Victor Webb,
Marston Webb International
|
|
|
T: (212)
684-6601
|
|
|
e-mail:
marwebint@cs.com
|
|
|
SOURCE Sunridge International
Copyright . 24 PR Newswire
